Indazole partial agonists targeting peripheral cannabinoid receptors.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Neuroscience

Background:

• Limited research exists on partial agonists of cannabinoid receptors (CBRs) and their structure-activity relationships (SAR).
• Partial CBR agonists may offer prolonged efficacy, reduced tolerance, and fewer psychiatric effects compared to full agonists.

Purpose of the Study:

• To investigate the SAR for converting indazole full agonists into peripheral partial agonists.
• To identify novel partial CBR agonists with potential therapeutic applications.

Main Methods:

• Structure-activity relationship (SAR) studies were conducted.
• Pharmacological profiling of synthesized compounds, including EC50 and Emax determination.
• Pharmacokinetic (PK) studies in mice to assess oral absorption, half-life, and brain penetrance.

Main Results:

• Compound 45 identified as a partial CBR agonist with specific EC50 and Emax values at human CB1 and CB2 receptors.
• Compound 45 demonstrated peripheral selectivity.
• Mouse PK studies showed oral absorption, a plasma half-life of approximately 7.3 hours, and less than 10% brain penetrance.

Conclusions:

• The study successfully developed partial CBR agonists with peripheral selectivity.
• Compound 45 represents a promising candidate for therapeutic applications in inflammatory diseases, GI disorders, and pain management.
• The findings contribute to understanding SAR for partial CBR agonists and their potential clinical benefits.